Cyclic pifithrin-α sensitizes wild type p53 tumor cells to antimicrotubule agent-induced apoptosis

Neoplasia

Volumn 10, Issue 6, 2008, Pages 587-596

  Zuco, Valentina ^a   Zunino, Franco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 1; PACLITAXEL; PIFITHRIN ALPHA; POLO LIKE KINASE 1; PROTEIN P21; PROTEIN P53; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE M PHASE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; DOWN REGULATION; ENZYME PHOSPHORYLATION; FIBROBLAST; HUMAN; HUMAN CELL; MICROTUBULE; MITOSIS INHIBITION; MITOSIS SPINDLE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN FUNCTION;

EID: 44449137138     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.08262     Document Type: Article

References (39)

1. Haupt S, Berger M, Goldberg Z, and Haupt Y (2003). Apoptosis - the p53 network. J Cell Sci 116, 4077-4085.
2. Römer L, Klein C, Dehner A, Kessler H, and Buchner J (2006). p53 - A natural cancer killer: structural insights and therapeutic concepts. Angew Chem Int Ed Engl 45, 6440-6460.
3. Toledo F and Wahl GM (2006). Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 6, 909-923.
4. Alimirah F, Panchanathan R, Chen J, Zhang X, Ho S-M, and Choubey D (2007). Expression of androgen receptor is negatively regulated by p53. Neoplasia 9, 1152-1159.
5. Alimirah F, Panchanathan R, Davis FJ, Chen J, and Choubey D (2007). Restoration of p53 expression in human cancer cell lines upregulates the expression of notch: implications for cancer cell fate determination after genotoxic stress. Neoplasia 9, 427-434.
6. Meek DW (2000). The role of p53 in the response to mitotic spindle damage. Pathol Biol 48, 246-254.
7. Tarapore P and Fukasawa K (2002). Loss of p53 and centrosome hyperamplification. Oncogene 21, 6234-6240.
8. Burns TF, Fei P, Scata KA, Dicker DT, and El-Deiry WS (2003). Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells. Mol Cell Biol 23, 5556-5571.
9. Castedo M, Perfettini J-L, Roumier T, Andreau K, Medema R, and Kroemer G (2004). Cell death by mitotic catastrophe: a molecular definition. Oncogene 23, 2825-2837.
10. Vogel C, Kienitz A, Hofmann I, Müller R, and Bastians H (2004). Crosstalk of the mitotic spindle assembly checkpoint with p53 to prevent polyploidy. Oncogene 23, 6845-6853.
11. Blagosklonny MV (2006). Prolonged mitosis versus tetraploid checkpoint. Cell Cycle 5, 971-975.
12. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC, and Zunino F (1996). Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 56, 556-562.
13. Weller M (1998). Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res 292, 435-445.
14. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, and Vegelstein B (1999). Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104, 263-269.
15. Perego P, Romanelli S, Carenini N, Magnani I, Leone R, Bonetti A, Paolicchi A, and Zunino F (1998). Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to paclitaxel. Ann Oncol 9, 423-430.
16. Cassinelli G, Supino R, Perego P, Polizzi D, Lanzi C, Pratesi G, and Zunino F (2001). A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes. Int J Cancer 92, 738-747.
17. Gudkov AV and Komarova EA (2005). Prospective therapeutic applications of p53 inhibitors. Biochem Biophys Res Commun 331, 726-736.
18. Barchechat SD, Tawatao RI, Corr M, Carson DA, and Cottam HB (2005). Inhibitors of apoptosis in lymphocytes: synthesis and biological evaluation of compounds related to pifithrin-α. J Med Chem 48, 6409-6422.
19. Zuco V, Zanchi C, Lanzi C, Beretta GL, Supino R, Pisano C, Barbarino M, Zanier R, Bucci F, Aulicino C, et al. (2005). Development of resistance to the atypical retinoid, ST1926, in the lung carcinoma cell line H460 is associated with reduced formation of DNA strand breaks and a defective DNA damage response. Neoplasia 7, 667-677.
20. Drewinko B, Loo TL, Brown JA, Gottlieb JA, and Freireich EJ (1976). Combination chemotherapy in vitro with adriamycin. Observations of additive, antagonistic, and synergistic effects when used in two-drug combination on cultured human lymphoma cells. Cancer Biochem Biophys 1, 187-195.
21. Chou TC and Talalay P (1984). Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22, 27-55.
22. Blagosklonny MV, Giannakakou P, El-Deiry WS, Kingston DG, Higgs PI, Neckers L, and Fojo T (1997). Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res 57, 130-135.
23. 2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. Oncogene 20, 3806-3813.
24. Panno ML, Giordano F, Mastroianni F, Morelli C, Brunelli E, Palma MG, Pellegrino M, Aquila S, Miglietta A, Mauro L, et al. (2006). Evidence that low doses of taxol enhance the functional transactivatory properties of p53 on p21 waf promoter in MCF-7 breast cancer cells. FEBS Letters 580, 2371-2380.
25. Ling Y-H, Tornos C, and Perez-Soler R (1998). Phosphorylation of Bcl-2 is a marker of M phase events and not a determinant of apoptosis. J Biol Chem 273, 18984-18991.
26. Van Vugt MATM and Modema RH (2005). Getting in and out of mitosis with polo-like kinase-1. Oncogene 24, 2844-2859.
27. Bhalla KN (2003). Microtubule-targeted anticancer agents and apoptosis. Oncogene 22, 9075-9086.
28. Carvajal D, Tovar C, Yang H, Vu BT, Heimbrook DC, and Vassilev LT (2005). Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res 65, 1918-1924.
29. 2 DNA damage checkpoint. J Biol Chem 275, 30638-30643.
30. 2/M transition. Biochim Biophys Acta 1519, 1-12.
31. 1-S cell cycle checkpoint function sensitizes cells to microtubule inhibitor-induced apoptosis. Cancer Res 59, 3831-3837.
32. Van Vugt MATM, Bras A, and Medema RH (2005). Restarting the cell cycle when the checkpoint comes to a halt. Cancer Res 65, 7037-7040.
33. 2M arrest and attenuates mitochondrial injury and apoptosis in p53-null human leukemia cells. Cell Cycle 3, 1305-1311.
34. cdc2 kinase. Mol Cell 2, 581-591.
35. Barboule N, Chadebech P, Baldin V, Vidal S, and Valette A (1997). Involvement of p21 in mitotic exit after paclitaxel treatment in MCF-7 breast adenocarcinoma cell line. Oncogene 15, 2867-2875.
36. 2-M arrest and apoptosis induced by paclitaxel in human sarcoma cells lacking both p53 and functional Rb protein. Mol Pharmacol 55, 1088-1093.
37. Heliez C, Baricault L, Barboule N, and Valette A (2003). Paclitaxel increases p21 synthesis and accumulation of its AKT-phosphorylated form in the cytoplasm of cancer cells. Oncogene 22, 3260-3268.
38. Sohn D, Essmann F, Schulze-Osthoff K, and Janicke RU (2006). P21 blocks irradiation-induced apoptosis downstream of mitochondria by inhibition of cyclic-dependent kinase-mediated caspase-9 activation. Cancer Res 66, 11254-11262.
39. Pasquier E, Honoré S, and Braguer D (2006). Microtubule-targeting agents in angiogenesis: where do we stand? Drug Resist Updat 9, 74-86.